Back HCV Treatment

HCV Treatment

3. High Hepatitis C Treatment Cost Leads to Restrictions, Sets Off Price War

The high cost of new interferon-free hepatitis C treatments has raised concerns about how public payers and private insurers will be able to afford them and sparked a more general discussion about the cost of pharmaceuticals in a changing healthcare landscape.

alt

Read more:

9. Evolving Hepatitis C Therapy Guidelines and Treatment Cascade

The first U.S. hepatitis C treatment guidelines incorporating interferon-free direct-acting antiviral regimens were issued in January 2014 and periodically updated to reflect new drug approvals and emerging data from studies and real-world use. The new therapies have cure rates above 90%, but cost and other barriers have limited their use.

alt

Read more:

AASLD 2014: ACH-3102 plus Sofosbuvir Cures All Hepatitis C Patients in Phase 2 Study

Achillion's second-generation HCV NS5A inhibitor ACH-3102 combined with sofosbuvir (Sovaldi) was well-tolerated and led to sustained virological response in all treatment-naive genotype 1 hepatitis C patients in a Phase 2 proxy study, according to late-breaking findings presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meetinglast month in Boston. Another early study showed promising results for Achillion's nucleotide polymerase inhibitor ACH-3422.

alt

Read more:

Updated Hepatitis C Treatment Guidelines Add New Therapies, Hard-to-Treat Patients

The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA), and International Antiviral Society-USA (IAS-USA) recently updated their hepatitis C treatment guidelines to add newly approved interferon-free direct-acting antiviral regimens and to provide more information about treating patients with HIV/HCV coinfection and decompensated liver disease. The evolving guidelines are available online at HCVguidelines.org.

alt

Read more:

AbbVie's Viekira "3D" Combo for Hepatitis C Wins FDA Approval

The U.S. Food and Drug Association this week approved AbbVie's Viekira Pak for people with genotype 1 chronic hepatitis C, including patients with compensated cirrhosis. The regimen -- formerly known as "3D" -- consists of the HCV NS3/4A protease inhibitor paritaprevir, a ritonavir booster, and the NS5A inhibitor ombitasvir in a once-daily coformulation, taken with the twice-daily non-nucleoside HCV NS5B polymerase inhibitor dasabuvir.

alt

Read more: